Data gathered: January 2
AI Stock Analysis - Geovax Labs (GOVX)
Analysis generated August 19, 2024. Powered by Chat GPT.
GeoVax Labs (NASDAQ: GOVX) is a biotechnology company focused on developing human vaccines and immunotherapies against infectious diseases and cancers. The company's innovative platform uses the Modified Vaccinia Ankara (MVA) virus to express antigens with minimal side effects. Notably, GeoVax is actively working on projects addressing HIV/AIDS, Zika virus, and even COVID-19, among others. This strategic focus on critical, high-impact health issues places GeoVax in a distinct position within the biotech sector.
Stock Alerts - Geovax Labs (GOVX)
 |
Geovax Labs | December 31 Price is up by 6.2% in the last 24h. |
|
Geovax Labs | December 30 Price is down by -5.7% in the last 24h. |
|
Geovax Labs | December 27 Price is up by 5.5% in the last 24h. |
|
Geovax Labs | December 23 Price is down by -5.2% in the last 24h. |
Alternative Data for Geovax Labs
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 499 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 14,780 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,627 | Sign up | Sign up | Sign up |
| Twitter Mentions | 13 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 88 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 26 | Sign up | Sign up | Sign up |
About Geovax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.
| Price | $2.39 |
| Target Price | Sign up |
| Volume | 204,360 |
| Market Cap | $23M |
| Year Range | $1.11 - $8.35 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Financial Comparison: GeoVax Labs (NASDAQ:GOVX) vs. Silverback Therapeutics (NASDAQ:SBTX)January 1 - ETF Daily News |
|
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by BrokeragesDecember 31 - ETF Daily News |
|
GeoVax Labs (NASDAQ:GOVX) to Reconvene Special Stockholders MeetingDecember 20 - ETF Daily News |
 |
GeoVax Labs (NASDAQ:GOVXW) Stock Price Down 14.1% – Here’s WhyDecember 19 - ETF Daily News |
|
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Rating of “Buy” from BrokeragesDecember 5 - ETF Daily News |
|
Head to Head Review: China Pharma (NYSE:CPHI) versus GeoVax Labs (NASDAQ:GOVX)December 4 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2.8M | 1.2M | 1.5M | -5.8M | 0 | 0.000 |
| Q2 '24 | 300,000 | 1.1M | -790,000 | -5.1M | -5M | -1.990 |
| Q1 '24 | 0 | 1.5M | -1.5M | -5.9M | -5.9M | -2.470 |
| Q4 '23 | 100,000 | 1.5M | -1.5M | -7.6M | -7.7M | -13.600 |
| Q3 '23 | 0 | 1.7M | -1.7M | -8.4M | -8.6M | -0.320 |
Insider Transactions View All
| DODD DAVID A filed to buy 26,661 shares at $2. August 12 '24 |
| DODD DAVID A filed to buy 18,661 shares at $2.3. February 22 '24 |
| DODD DAVID A filed to buy 10,452 shares at $2.2. February 22 '24 |
| Reynolds Mark filed to buy 7,213 shares at $2.8. February 7 '24 |
| McKee Kelly T. Jr. filed to buy 35,782 shares at $0.4. December 26 '23 |
Similar companies
Read more about Geovax Labs (GOVX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Geovax Labs?
The Market Cap of Geovax Labs is $23M.
What is the current stock price of Geovax Labs?
Currently, the price of one share of Geovax Labs stock is $2.39.
How can I analyze the GOVX stock price chart for investment decisions?
The GOVX stock price chart above provides a comprehensive visual representation of Geovax Labs' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Geovax Labs shares. Our platform offers an up-to-date GOVX stock price chart, along with technical data analysis and alternative data insights.
Does GOVX offer dividends to its shareholders?
As of our latest update, Geovax Labs (GOVX) does not offer dividends to its shareholders. Investors interested in Geovax Labs should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Geovax Labs?
Some of the similar stocks of Geovax Labs are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.